CBI Pharma to Hold 6th Annual IVD Summit 2015 on March 12-13 in Shenzhen, China

SHANGHAI

CBI Pharma, a subsidiary of ENMORE, will hold the 6^th Annual IVD Summit 2015 (IVDS 2015) in Shenzhen, China on March 12-13, 2015. As the No.1 IVD industry summit in China, IVDS discusses industry policies and market trends and provides a good cooperation and communication platform for IVD industry players around the world.

China is the fastest increasing IVD market with a 16% average annual growth rate. At the same time, with the enhancement of China’s medical insurance policy and its popularization in rural areas, public awareness of medical treatment and healthcare will continue to rise. In the meantime, with the rapid growth of national economy and improvement of people’s living standards, the demand for IVD products will be sequentially increased. China’s IVD market holds tremendous potential.

However, China is faced with many restrictions like outdated laws and regulations, a low concentration rate for the industry, weak R&D capacity, lack of talent, intense homogenized competition and so on. To break the bottleneck, it’s necessary to enhance cooperation and communication among governments, manufacturers, institutions, end-users and investors.

IVDS 2015 will explore and present scientific, pragmatic, authoritative and up-to-date expertise and technologies to you. The participants will have great networking opportunities and get a thorough update about the policies and the market. Besides, cases will be studied to demonstrate how cutting-edge technologies have been turned into commercial success.

Topics to be covered include:

Development Tendency of IVD Industry during the “13^th Five-year Plan” Period in China
Global IVD Industry and Segment Market Analysis
Market Opportunities of Wearable Medical Equipment
Application Tendency of Next-generation Sequencing
Present Situation and Outlook of Pediatric Infectious Disease Virus Reagents
Present Situation and Future Forecast on POCT Market in China
Pharmacogenomics and Individualized Therapy
Performance Evaluation of IVD Products